The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.

Disclosures: Paula A Rochon, MD, MPH, FRCPC Nothing to disclose. Kenneth E Schmader, MD Grant/Research/Clinical Trial Support: Merck [Herpes Zoster (Zoster vaccine)]. H Nancy Sokol, MD Employee of UpToDate, Inc.

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.

Conflict of interest policy

All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Aug 2014. | This topic last updated: Mar 28, 2014.

INTRODUCTION — Optimizing drug therapy is an essential part of caring for an older person. The process of prescribing a medication is complex and includes: deciding that a drug is indicated, choosing the best drug, determining a dose and schedule appropriate for the patient's physiologic status, monitoring for effectiveness and toxicity, educating the patient about expected side effects, and indications for seeking consultation.

Avoidable adverse drug events are the serious consequences of inappropriate drug prescribing. The possibility of an adverse drug event should always be borne in mind when evaluating an older adult individual; any new symptom should be considered drug-related until proven otherwise.

Prescribing for older patients presents unique challenges. Premarketing drug trials often exclude geriatric patients and approved doses may not be appropriate for older adults [1]. Many medications need to be used with special caution because of age-related changes in pharmacokinetics (ie, absorption, distribution, metabolism, and excretion) and pharmacodynamics (the physiologic effects of the drug).

Particular care must be taken in determining drug dosages when prescribing for older adults. An increased volume of distribution may result from the proportional increase in body fat relative to skeletal muscle with aging. Decreased drug clearance may result from the natural decline in renal function with age, even in the absence of renal disease [2]. Larger drug storage reservoirs and decreased clearance prolong drug half-lives and lead to increased plasma drug concentrations in older people.

As examples, the volume of distribution for diazepam is increased, and the clearance rate for lithium is reduced, in older adults. The same dose of either medication would lead to higher plasma concentrations in an older, compared to younger, patient. Also, from the pharmacodynamic perspective, increasing age may result in an increased sensitivity to the effects of certain drugs, including benzodiazepines [3-6] and opioids [7].

A stepwise approach to optimized prescribing of drug therapy for older adults will be reviewed here. Drug treatments for specific conditions in the older population are discussed separately.

MEDICATION USE BY OLDER ADULTS — Medications (prescription, over-the-counter, and herbal preparations) are widely used by older adults. A survey in the United States of a representative sampling of 3005 community dwelling adults (aged 57 through 85 years) was conducted by in-home interviews and use of medication logs between 2005 and 2006 [8]. At least one prescription medication was used by 81 percent. Five or more prescription medications were used by 29 percent of the overall survey population and by 36 percent of people aged 75 to 85 years. Forty-six percent of prescription users also took at least one over-the- counter medication.

Herbal and dietary supplements — Use of herbal or dietary supplements (eg, ginseng, ginkgo biloba extract, and glucosamine) by older adults has been increasing, from 14 percent in older women in 1998 [9] to 26 to 27 percent in 2002 [10,11] and 49 percent in 2006 [8]. One study in over 3000 ambulatory adults 75 years of age or older in four states in the US found that almost three-quarters used at least one prescription drug and one dietary supplement [12]. Often, clinicians do not question patients about use of herbal medicines and patients do not routinely volunteer this information. In one US survey, three-quarters of respondents aged 18 years and older reported that they did not inform their clinician that they were using unconventional medications [13].

Herbal medicines may interact with prescribed drug therapies and lead to adverse events, underscoring the importance of routinely questioning patients about the use of unconventional therapies. Examples of herbal-drug therapy interactions include ginkgo biloba extract taken with warfarin, causing an increased risk of bleeding, and St. John's wort taken with serotonin-reuptake inhibitors, increasing the risk of serotonin syndrome in older adults [14]. A study of the use of 22 supplements in a survey of 369 patients aged 60 to 99 years found potential interactions between supplements and medications for 10 of the 22 supplements surveyed [15]. (See "Overview of herbal medicine and dietary supplements", section on 'Herb-drug interactions'.)

Many older adults receive their information about herbal products from the internet. Eighty percent of 338 retail web sites identified in a search of the eight most widely used herbal supplements (ginkgo biloba, St. John's wort, echinacea, ginseng, garlic, saw palmetto, kava, and valerian root) made at least one health claim suggesting that the therapy could treat, prevent, or even cure specific conditions [16].

QUALITY MEASURES OF DRUG PRESCRIBING — Multiple factors contribute to the appropriateness and overall quality of drug prescribing. These include avoidance of inappropriate medications, appropriate use of indicated medications, monitoring for side effects and drug levels, avoidance of drug-drug interactions, and involvement of the patient and integration of patient values [17].

Measures of the quality of prescribing often focus on one or some of these factors, but rarely on all. Furthermore, the predictive value of these measures of "quality of prescribing" in determining important long-term outcomes of care have not been determined. Approaches to decrease inappropriate prescribing in older adults include educational interventions, computerized order entry and decision support, multidisciplinary team care led by physicians, clinical pharmacists, and combinations of these approaches. Available data for these interventions generally show significant improvements in inappropriate prescribing but mixed results for health outcomes or costs [17,18]. A 2013 systematic review of eight studies of different prescribing interventions in long-term care homes (medication review, case conferences, staff education, clinical decision support technology, and/or some combination of these) showed no effect of the interventions on hospital admissions, adverse drug events (ADEs), and mortality [18]. The studies that evaluated medication-related problems, appropriate prescribing, or cost of medication showed some evidence that interventions helped the recognition and solving of medication problems. A previous 2008 systematic review of 10 studies of computerized physician order entry with clinical decision support showed a mixed effect on reduction in ADEs, with five studies that showed a statistically-significant reduction in ADEs, four that showed nonsignificant decrease, and one study that showed no impact on rate of ADEs [19].

POLYPHARMACY — Polypharmacy is defined simply as the use of multiple medications by a patient. The precise minimum number of medications used to define “polypharmacy” is variable, but generally ranges from 5 to 10 [20]. While polypharmacy most commonly refers to prescribed medications, it is important to also consider the number of over-the-counter and herbal/supplements used.

The issue of polypharmacy is of particular concern in older people who, compared to younger individuals, tend to have more disease conditions for which therapies are prescribed. It has been estimated that 20 percent of Medicare beneficiaries have five or more chronic conditions and 50 percent receive five or more medications [21].

The use of greater numbers of drug therapies has been independently associated with an increased risk for an adverse drug event, irrespective of age [22].

There are multiple reasons why older adults are especially impacted by polypharmacy:

Older individuals are at greater risk for adverse drug events due to metabolic changes and decreased drug clearance associated with aging; this risk is compounded by increasing numbers of drugs used.

Polypharmacy increases the potential for drug-drug interactions and for prescription of potentially inappropriate medications [23].

Polypharmacy was an independent risk factor for hip fractures in older adults in one case-control study, although the number of drugs may have been an indicator of higher likelihood of exposure to specific types of drugs associated with falls (eg, CNS active drugs) [24].

Polypharmacy increases the possibility of “prescribing cascades” [25]. A prescribing cascade develops when an adverse drug event is misinterpreted as a new medical condition and additional drug therapy is then prescribed to treat this medical condition. (See 'Prescribing cascades' below.)

Use of multiple medications can lead to problems with medication adherence, compounded by visual or cognitive compromise in many older adults.

A balance is required between over- and underprescribing. Multiple medications are often required to manage clinically complex older adults. Clinicians are often challenged with the need to match the complex needs of their older patients with those of disease-specific clinical practice guidelines. For a hypothetical older female patient with chronic obstructive pulmonary disease, type 2 diabetes, osteoporosis, hypertension and osteoarthritis, clinical practice guidelines would recommend prescribing 12 medications for this individual [26].

A more systematic approach is required to guide the tailoring of medication regimens to the needs of individuals. One important principle is to match the medication regimen to the patient’s condition and goals of care. This includes a careful consideration of the medications that should be discontinued or substituted [27] (table 1).

It is particularly important to reconsider medication appropriateness late in life. A model for appropriate prescribing for patients late in life has been proposed [28] (table 2). The process considers the patients’ remaining life expectancy and the goals of care in reviewing the need for existing medications and in making new prescribing decisions. For example, if a patient’s life expectancy is short and the goals of care are palliative then prescribing a prophylatic medication requiring several years to realize a benefit may not be considered appropriate. This is increasingly being recognized as an important consideration when managing individuals with advanced dementia [29]. Additionally, therapeutic medications (eg, antibiotics for pneumonia) may not increase comfort or quality of life when palliative care is the objective [30].

INAPPROPRIATE MEDICATIONS — Various criteria have been developed by expert panels in Canada [31] and in the United States [32-37] to assess the quality of prescribing practices and medication use in older adult individuals. The most widely used criteria for inappropriate medications are the Beers criteria. (See 'Beers criteria' below.)

In another approach, a Drug Burden Index has been modelled incorporating drugs with anticholinergic or sedative effects, total number of medications, and daily dosing [38,39]. An increased drug burden for anticholinergic and sedative medications was associated with impaired performance on mobility and cognitive testing in high-functioning community-based older adults. Total number of medications was not associated with impaired performance when sedatives and anticholinergics were excluded. A high Drug Burden Index has been correlated with increased risk for functional decline in community dwellers [39] and with increased risk of falls in residents in long-term care facilities [40].

Anticholinergic activity — Anticholinergic medications are associated with multiple adverse effects to which older individuals are particularly susceptible. These adverse effects include memory impairment, confusion, hallucinations, dry mouth, blurred vision, constipation, nausea, urinary retention, impaired sweating, and tachycardia. Anticholinergics can precipitate an acute glaucoma episode in patients with narrow angle glaucoma and acute urinary retention in patients with benign prostatic hypertrophy. In a population study of 6912 men and women 65 years and older, those taking anticholinergic drugs were at increased risk for cognitive decline and dementia and risk decreased with medication discontinuation [41]. In another population of 13,004 individuals aged 65 and older, use of anticholinergic medications was also shown to be associated with greater decline in cognition as measured by the Mini-Mental State Examination [42]. In addition, anticholinergic medication use was associated with increased mortality over a two year period after adjustment for multiple factors, including comorbid health conditions. Nonetheless, an analysis of US medication expenditures between 2005 and 2009 found that 23.3 percent of community-dwelling persons >65 years with dementia were prescribed medications with clinically-significant anticholinergic activity [43].

A scale of risk for adverse events related to specific drugs with anticholinergic properties has been developed and prospectively validated in a population primarily composed of older male patients [44], although its utility in clinical practice has not been determined. A higher anticholinergic risk score correlated with risk for both central (falls, dizziness, confusion) and peripheral (dry mouth, dry eyes, constipation) adverse events (table 3).

A study measured the in vitro anticholinergic activity (AA) of 107 medications commonly used in older adults [45]. At usual doses, AA was most significantly elevated for amitriptyline, atropine, clozapine, dicyclomine, doxepin, L-hyoscyamine, thioridazine, and tolterodine. AA also was increased for chlorpromazine, diphenhydramine, nortriptyline, olanzapine, oxybutynin, and paroxetine. It should be noted, however, that higher doses of an agent with relatively low or moderate AA can produce significant AA effects. Additionally, the cumulative effects of more than one agent with low AA can produce significant AA effects.

Alternative drugs with lower AA are available in many classes represented by these drugs. However, adverse drug reactions other than AA should also be taken into account in weighing the clinical benefits of possible substitutions (eg dyskinesias and sedation with haloperidol and perphenazine).

Beers criteria — The Beers criteria, initially developed by an expert consensus panel in 1991 to target nursing home residents, are the most widely-cited criteria used to assess inappropriate drug prescribing [32]. The panel produced a list of medications considered inappropriate for older patients, either because of ineffectiveness or high risk for adverse events.

The original Beers criteria have been revised in 1997, 2003, and most recently in 2012 [33,34,46]. The 2012 revised Beers criteria are available through the American Geriatrics Society website. The criteria include 53 medications designated in one of three categories: those that should always be avoided (eg, barbiturates, chlorpropamide); those that are potentially inappropriate in older adults with particular health conditions or syndromes; and those that should be used with caution. New additions to the 34 potentially-inappropriate medications include sliding scale insulin, glyburide, and megestrol. Thiazolidinediones should be avoided in patients with heart failure, and selective serotonin reuptake inhibitors (SSRIs) in patients with falls and fractures.

Several studies, using older versions of the Beers criteria, have identified that use of drugs identified as “inappropriate” was widespread in the United States, Canada, and Europe [47-49].

Some of the inappropriate drug therapies identified on the Beers list are available as over-the-counter products [50]. This reinforces the need to always consider over-the-counter drug therapies when reviewing a patient's medications and to educate individuals on potential problems that can arise from the use of over-the-counter preparations.

The Beer's criteria are increasingly being used to monitor quality of care for older adults. The validity of these consensus-derived criteria in predicting adverse outcomes therefore is becoming increasingly more important. Studies of earlier versions of the Beers criteria did predict adverse outcomes but that some medications not on the earlier criteria correlated more closely with adverse outcomes:

Data from the 1996 Medical Expenditure Panel survey showed that risks of hospitalization and death were greater for nursing home patients who had been prescribed medications defined as potentially inappropriate by the 2003 combined Beers criteria [51].

A systematic review of 18 retrospective cohort studies found that for patients >65 years old in the community setting, inappropriate medication use (defined by Beers criteria 1991, 1997, and 2003) was associated with increased hospitalization rates but not mortality; for patients in the nursing home setting, the relationship between inappropriate medications and hospitalization rates was inconclusive [52].

A study that used electronic data to survey adverse drug events associated with emergency department visits for patients ≥ 65 years of age found that drugs meeting Beers criteria for always potentially inappropriate accounted for 3.6 percent (95% CI 2.8-4.5 percent) of the estimated 178,000 visits [53]. Three medications not on the Beers list (warfarin, digoxin, and insulin) accounted for 33.3 percent (95% CI 27.8-38.7 percent) of the visits, and medications in the general class of anticoagulants or antiplatelet agents, antidiabetic agents, and narrow therapeutic index agents accounted for nearly half of all visits, though were prescribed in only 9.4 percent of patients seen.

Similar methodology was used by the same group to evaluate adverse drug events (ADEs) resulting in emergency hospitalizations among older Americans [54]. Four types of medication (warfarin, insulin, oral antiplatelet agents, and oral hypoglycemics) accounted for 67.0 percent of the ADEs, while 6.6 percent of the hospitalizations were attributed to Beers-criteria potentially-inappropriate medications.

Other criteria sets — The Screening Tool of Older Person's Prescriptions (STOPP) criteria were introduced in 2008 [55,56]. The 2003 Beers criteria have been compared to the Screening Tool of Older Person's Prescriptions (STOPP), another tool for identifying inappropriate prescribing, in terms of their correlation with ADEs [57]. STOPP and Beers criteria overlapped in several areas, but earlier versions of the Beers criteria used in this comparison contained some drugs no longer in common use, and STOPP includes consideration of drug-drug interactions and duplication of drugs within a class. In two studies, STOPP identified a significantly-higher proportion of older people requiring hospitalization as a result of a medication-related adverse event than did the 2003 Beers criteria [55,57].

The FORTA (Fit FOR The Aged) list identifies medications rated in four categories (clear benefit; proven but limited efficacy or some safety concerns; questionable efficacy or safety profile - consider alternative; clearly avoid and find alternative) with ratings based on the individual patient’s indication for the medication [58]. The tool, developed in Germany, has undergone consensus validation with a panel of geriatricians [59], but studies of its impact on clinical outcomes are ongoing.

Health Care Financing Administration — The Centers for Medicare and Medicaid Services drug utilization review criteria target eight prescription drug classes (digoxin, calcium channel blockers, angiotensin-converting enzyme inhibitors, H-2 receptor antagonists, NSAIDs, benzodiazepines, antipsychotics, and antidepressants) and focus on four types of prescribing problems (inappropriate dosage, inappropriate duration of therapy, duplication of therapies, and potential for drug-drug interactions). In one study, 19 percent of 2508 community dwelling older adults were using one or more medications inappropriately; NSAIDs and benzodiazepines were the drug classes with the most potential problems [36].

Assessing Care of Vulnerable Elders (ACOVE) project — Another expert panel has identified quality indicators for appropriate medication use as part of the Assessing Care of Vulnerable Elders (ACOVE) project [60,61]. These indicators begin with practical suggestions on how to improve prescribing practices:

Document the indication for a new drug therapy

Educate patients on the benefits and risks associated with the use of a new therapy

Maintain a current medication list

Document response to therapy

Periodically review the ongoing need for a drug therapy

In addition, these indicators specify drug therapies that either should not be prescribed for older adults or that warrant careful monitoring after they have been initiated (table 4).

UNDERUTILIZATION OF APPROPRIATE MEDICATION — Much attention has been paid to over-prescribing for older adults; under-prescribing appropriate medications is also of concern. Prescribing strategies that seek to simply limit the overall number of drugs prescribed to older adults in the name of improving quality of care may be seriously misdirected.

Clinicians may be better at avoiding over-prescribing of inappropriate drug therapies than at prescribing indicated drug therapies. As an example, one study of older adults (n = 372) in two managed care organizations found that 50 percent had not been prescribed some recommended therapy, while only 3 percent were prescribed medications classified as inappropriate [62]. However, under- and overutilization of medications were equally prevalent in another study [63]. In a VA outpatient population, mean age 75 years (n = 196), inappropriate medications were documented for 65 percent and medication underuse for 64 percent; simultaneous under and overutilization occurred in 42 percent of patients.

However, it should also be recognized that determination of "under-prescribing" is based on guidelines that address individual disease entities, while most geriatric patients have multiple conditions [21]. As an example, a patient with a myocardial infarction, history of diabetes, and elevated lipids would require a beta-blocker, ACE inhibitor, aspirin, statin, and a hypoglycemic medication. Accordingly, many older adults need to take six or more essential medications. In this context, clinicians may make informed decisions to "underprescribe," to foster compliance with essential medications, limit drug interactions, and prioritize health benefits for active treatment of serious conditions over preventive therapies or conditions that have less impact on quality of life.

Factors leading to unintended underutilization include clinicians not recognizing medication benefit in the older population, affordability, and dose availability.

Medication effectiveness — Studies of drug effectiveness specifically often exclude the geriatric population, due to concerns with comorbidities and side effects causing difficulty in interpretation of study results. Therefore, the benefit of treatment for older adults, especially for preventive purposes, may not be established or may not be recognized by prescribing clinicians. As an example, in a study of statin use for secondary prevention in patients over age 66, the likelihood of being prescribed statin therapy declined 6.4 percent for every year of age; overall, only 19 percent of patients in this high risk population had been prescribed a statin [64].

Affordability — A prescription may be written but not filled, or filled and not taken regularly, due to financial considerations. This may be a particular problem in countries where there is no universal insurance coverage for drug therapy for older adults.

Enhanced drug coverage for older adults can be a powerful incentive to improve the use of beneficial therapies. A comparison of two groups of Medicare patients, as an example, found that statin use was 4.1 percent in patients without drug coverage and 27 percent in those with drug benefits [65]. Significant utilization differences between insured and uninsured patients were seen even for the use of inexpensive medications such as beta-blockers and nitrates.

Cost-related medical noncompliance affected almost 30 percent of disabled Medicare enrollees in 2004, and noncompliance rates were significantly higher for patients with multiple comorbidities [66].

Additional information on the affordability of medications can be found elsewhere in UpToDate. (See "Patient information: Reducing the costs of medicines (Beyond the Basics)".)

Dose availability — Older individuals often require lower than usual doses of medications, especially at initiation. If medications are not readily available in prescribed doses, the need to split tablets may make it more difficult for patients to take beneficial drug therapy [67].

ADVERSE DRUG EVENTS (ADES) — A number of factors in older individuals contribute to their increased risk for developing a drug-related problem. These include frailty, coexisting medical problems, memory issues, and use of multiple prescribed and non-prescribed medications [68].

Drug-related hospitalizations account for 2.4 to 6.5 percent of all medical admissions in the general population; the proportion is much higher for older patients [69-71]. In the United States, it is estimated that annually from 2007 to 2009 there were 99,628 emergency hospitalizations for adverse drug events in individuals 65 years and older, with two-thirds due to unintentional overdoses [54]. A meta-analysis found a fourfold increase in the rate of hospitalization related to adverse drug events in older adults compared with younger adults (16.6 versus 4.1 percent); it was estimated that 88 percent of the ADE hospitalizations among older adults were preventable, compared with 24 percent among young persons [72].

Adverse drug reactions (ADRs) are noxious responses to drugs used in usual doses for treatment or prevention of disease. Adverse drug events (ADEs) are any injury that occurs from a drug, including noxious responses, drug administration errors, and any other circumstances that lead to an injury.

Prescribing cascades — Prescribing cascades occur when a new drug is prescribed to treat symptoms arising from an unrecognized adverse drug event related to an existing therapy [25]. The patient is then at risk for developing additional adverse drug events related to the new and potentially unnecessary treatment (table 5). Older adults with chronic disease and multiple drug therapies are at particular risk for prescribing cascades.

Drug-induced symptoms in an older person can be easily misinterpreted as indicating a new disease or can be attributed to the aging process itself rather than the drug therapy. This misinterpretation is particularly likely when the drug-induced symptoms are indistinguishable from illnesses that are common in older persons. Selected examples of prescribing cascades are described below.

One of the best recognized examples of a prescribing cascade relates to the initiation of anti-Parkinson therapy for symptoms arising from use of drugs such as antipsychotics [73-75] or metoclopramide [76]. The anti-Parkinson drugs can then lead to new symptoms, including orthostatic hypotension and delirium.

In a case-control study of 3512 Medicaid patients (age 65 to 99 years), patients who had received an antipsychotic medication in the preceding 90 days were 5.4 times more likely to be prescribed anti-Parkinson therapy than patients who had not received an antipsychotic (95% CI 4.8-6.1) [73].

Some prescribing cascades may be less obvious, especially for drugs whose adverse events are not as commonly recognized. As an example, cholinesterase inhibitors (eg, donepezil, rivastigmine, and galantamine) are commonly used for the management of dementia symptoms in older adults. The adverse events associated with these drugs can be viewed as the reverse of those that might be expected with anticholinergic therapies. Accordingly, while anticholinergic therapies may cause constipation and urinary retention, cholinesterase inhibitors may cause diarrhea and urinary incontinence. A prescribing cascade occurs when the prescription of a cholinesterase inhibitor is followed by a prescription for an anticholinergic therapy (eg, oxybutynin) to treat incontinence.

A retrospective cohort study in older adults in Canada (n = 44,884) found that the risk of treatment with an anticholinergic medication for urinary incontinence was greater for patients who had received a cholinesterase inhibitor (adjusted hazard ratio 1.53; 95% CI 1.39-1.72) [77]. This study suggests that clinicians should consider the possible contributing role of cholinesterase inhibitors in new-onset or worsening urinary incontinence.

Drug-drug interactions — Older adults are particularly vulnerable to drug-drug interactions because they often have multiple chronic medical conditions requiring multiple drug therapies. The risk of an adverse event due to drug-drug interactions is substantially increased when multiple drugs are taken [78-82]. As an example, the risk of bleeding with warfarin therapy is increased with coadministration of selective and non-selective NSAIDs, SSRIs, omeprazole, lipid-lowering agents, amiodarone, and fluorouracil [78].

A case control study from Canada evaluated hospitalizations for drug-related toxicity in a population of older patients who had received one of three common drug therapies used in older adults: glyburide, digoxin, or ACE inhibitor [82]. Hospitalization for hypoglycemia was six times more likely in patients who had received co-trimoxazole. Digoxin toxicity was 12 times more likely for patients who had been started on clarithromycin. Hyperkalemia was 20 times more likely for patients who were treated with a potassium sparing diuretic.

Care must be taken when prescribing any medication, especially for the older individual, to review existing medications and consider potential drug interactions.

Dose-related adverse drug events — Adverse drug events are often dose-related. Examples include:

A case-control study from the 1980's related risk of hip fracture in a Medicaid population with use and dose of psychotropic drugs [83]. A dose-related effect was seen for use of long half-life hypnotic-anxiolytics, tricyclic antidepressants, or neuroleptic therapy, and hospitalization for hip fracture.

A study of people 65 years and older in Quebec (n >250,000) found that more than a quarter (27.6 percent) were dispensed at least one prescription for a benzodiazepine [84]. The risk of injury was dose related for some benzodiazepines (oxazepam, flurazepam, and chlordiazepoxide) though not for alprazolam.

Dose of benzodiazepine, but not elimination half life, was related to risk for hip fracture in a case control study of adults aged 55 years and older from the Netherlands [6].

Renal impairment — A common cause of dose-related adverse events in older adults is failure to properly adjust doses for renal insufficiency. Renal impairment becomes more common with advancing age. For patients with stable renal function, creatinine clearance can be estimated according to published formulas which factor age into the calculation (calculator 1). Because of decreased muscle mass in older adults, however, serum creatinine levels may not adequately reflect renal function; many older patients with a normal creatinine nonetheless have modestly impaired renal function. In one study, 40 percent of almost 10,000 older adults living in long-term care were found to have renal insufficiency [85]. In a community population over age 65 in France, the prevalence of renal insufficiency (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73m2) was 13.7 percent using the MDRD equation and 36.9 percent using the Cockcroft-Gault formula [86]. (See "Assessment of kidney function".)

Dosing guidelines for decreased creatinine clearance are available to calculate dose adjustments for medications that are cleared through the kidney [87]. The list of medications is long, and includes many antibiotics. In a community population, 52 percent of adults over age 65 with mild renal insufficiency were taking medications that required dose adjustment for low GFR; antihypertensives, fibrates, sedative/hypnotic, and anxiolytic medications accounted for most of these drugs [86]. The drug database (Lexi-Comp) available through UpToDate includes appropriate dose adjustments for renal function and for older adults, and can be accessed by searching on any individual drug. As a general rule, the initial dose for starting medications in older adults should be significantly reduced, and titrated up as tolerated by monitoring side effects or drug levels.

Decision aids have been moderately effective in decreasing the percentage of in-hospital prescriptions written with inappropriate adjustments for renal status (46 percent to 33 percent) [88].

Adverse drug events in long-term care setting — Long-term care residents are at a particularly high risk for developing adverse events [89]. The average US nursing home resident uses seven to eight different medications each month, and about one-third of residents have monthly drug regimens of nine or more medications [90].

A study of adverse drug events in two large academic long-term care facilities in the United States and Canada found 815 ADEs occurring during 8336 resident months [89]. The overall rate of adverse drug events was 9.8 per 100 resident–months; 42 percent of the ADEs were deemed preventable. Of the more serious adverse events, 61 percent were deemed preventable. The more serious the adverse event, the more likely it was to be considered potentially preventable. These rates were approximately four-times higher than had been previously reported [91], but may reflect the better documentation of ADEs at these institutions.

Preventable adverse drug events were most frequently associated with atypical antipsychotics and warfarin therapy (table 6). Neuropsychiatric events (confusion, oversedation, delirium), hemorrhagic, and gastrointestinal events were the most frequent types of ADEs in the long term care facilities studied (table 7). In a 12-month observational study of 490 long-term care residents taking warfarin in 25 nursing homes, there were 720 adverse drug events (625 minor, 82 serious, and 13 life-threatening); 57 percent of the serious events were considered preventable [92].

Atypical antipsychotics — Atypical antipsychotic medications, used for the management of the behavioral and psychological symptoms of dementia, are among the drugs most frequently associated with adverse events in long-term care facilities [89]. In particular, psychotropic medications are associated with an increased risk for falls. In one meta-analysis of patients age 60 or older, the odds ratio for any psychotropic use among patients who had one or more falls was 1.73 (95% CI 1.52-1.97) [93].

There is limited evidence to support the efficacy of these agents for management of behavioral and psychological symptoms in older adults. (See "Management of neuropsychiatric symptoms of dementia", section on 'Antipsychotic drugs' and "Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects".)

Nonetheless, use of antipsychotic medications in long term care facilities is widespread. A study of 19,780 older adults with no history of major psychosis prior to long-term care admission found that antipsychotic therapy was prescribed for 17 percent within 100 days of their long term care admission, and for 24 percent within one year [94]. A study of 485 nursing homes in Canada found that there was about a three-fold variation in antipsychotic prescribing, not related to clinical factors, between high- and low-prescribing facilities [95].

A public health advisory warning issued from the FDA warns of fatal adverse events in demented patients treated with atypical antipsychotic therapy [96-98]. Data from 17 trials of older adult patients with dementia have shown that those treated with atypical antipsychotic therapy were 1.6 to 1.7 times more likely to die than those given placebo therapy. Similar concerns have been raised for haloperidol and other conventional antipsychotics [99,100]. A retrospective comparison of patients with dementia who were newly treated with atypical antipsychotics, compared to no antipsychotics, found an increased risk of death at 30 and 180 days for the treated group (at 30 days, adjusted HR 1.55, 95% CI 1.15-2.07) [101]. Mortality was further increased, again by a factor of 1.55, for patients receiving conventional antipsychotics compared to atypical antipsychotics. These data point to the need to rethink the role of these therapies in clinical practice.

Predicting adverse drug reactions

A tool has been developed to identify older adult patients at increased risk for an ADR in hospital [102]. The tool, based on logistic regression analysis from a group of Italian patients mean age 78, and validated in a separate European cohort, found that the number of drugs prescribed and prior history of an ADR were the strongest predictors for a subsequent ADR. Compared to those receiving five or fewer medications, the risk of ADR was approximately doubled (OR 1.9, 95% CI 1.35-2.68) for those prescribed five to seven medications, and was fourfold (OR 4.07, CI 2.93-5.65) for those receiving eight or more medications. Other variables incorporated in this tool are the presence of four or more comorbid conditions, heart failure, liver disease, or renal failure.

Preventing adverse drug events — The occurrence of preventable adverse drug events is a significant concern. Inappropriate ordering and inadequate monitoring are the most common errors in preventable adverse drug events. Errors in transcription, dispensing, and administration are less commonly identified [89].

Medications that are commonly implicated in preventable adverse drug events are not generally those identified by widely utilized "bad drug" lists. "Good drugs" prescribed in an inappropriate manner may be far more problematic. When drugs do cause problems, it is often because they are prescribed, dosed, or monitored inappropriately.

Prevention of adverse drug events in the hospital setting is discussed separately. (See "Prevention of adverse drug events in hospitals".)

Long-term care — Enhanced surveillance and reporting systems for adverse drug events occurring in the nursing home setting are needed. Computerized order entry in the hospital setting has been shown to reduce serious medication errors [103]. A computer-based decision aid reduced in-hospital inappropriate dosing of psychotropic medications for geriatric inpatients [104]. However, a randomized trial of computerized order entry with clinical decision support in 29 resident care units at two longterm care facilities in Canada did not affect the rate of adverse drug events [105].

Community care — Patient errors in medication adherence are a significant contributor to adverse drug events for older patients living in the community, accounting for 21 percent of preventable ADEs in a large ambulatory Medicare population [106]. Patient errors occurred more frequently in patients who were regularly taking three or more medications, compared to those taking two or fewer [107].

Practical recommendations to reduce medical errors in the community have been proposed [108-113]:

Maintain an accurate list of all medications that a patient is currently using. This list should include the drug name (generic and brand), dosage, frequency, route, and indication.

Advise periodic "brown bag check-ups." Instruct patients to bring all pill bottles to each medical visit; bottles should be checked against the medication list.

Patients should be made aware of potential drug confusions: sound-alike names, look-alike pills, and combination medications.

Patients should be informed of both generic and brand names, including spelling, as well as the reasons for taking their medications. This may prevent unnecessary confusion when drugs are inconsistently labeled. As an example, a patient may be unaware that digoxin (generic) and Lanoxin (brand) are the same therapy.

Medication organizers that are filled by the patient, family member, or caregiver, can facilitate compliance with drug regimens. Blister packs for individual drugs, prepared by the pharmacist, can also be helpful in ensuring that patients take their medications correctly [112].

Community pharmacists are an important resource and can play a key role in working with older adults to reduce medication errors.

Transitions in care settings — Transitions in care, between hospital and nursing home, or institutional setting and home, are a common source of medication errors and confusions:

One Canadian multisite study found that 25 percent of 325 older adults experienced an ADE after discharge home from the hospital; half of these ADEs were considered preventable [108].

Changes in medication (different dose, discontinued therapies, additional therapies) were identified in 45 of 50 patients discharged from a geriatric ward in the UK within 6 to 14 days of discharge [109]. Of particular concern is discharge of older patients with new prescriptions for benzodiazepines that were initiated in the hospital, leading to unplanned chronic benzodiazepine use [114].

Attending physicians from an academic medical center reported that they believed 89 percent of their discharged patients (n = 99) understood potential side effects of their medications; 58 percent of those discharged patients reported that they understood this information [115].

Adverse drug events attributed to medication changes occurred in 20 percent of patients on transfer from hospital to a nursing home, occurring most commonly for patients being readmitted to the nursing home (12 of 14 events) [116].

Frail older people are often found to be on unnecessary drug regimens at the time of hospital discharge. Among 384 older veterans, 44 percent were found to have at least one unnecessary drug therapy at the time of discharge [117]. Factors contributing to this include multiple prescribers, "routine" medications for hospitalization such as antacids or stool softeners, and being on nine or more drug therapies.

Effort must be made to improve communication in "hand-offs" of patient care during transitions in care setting. This is particularly true when the physician responsible for the patient in the hospital is not the same as the physician providing the patient's longitudinal care. Accurate medication lists, direct communications between providers, and a thorough review of all medications at the time of care transition for appropriateness and intended duration of treatment, are steps that should be taken to avoid ADEs. Whenever possible, the number of prescribing physicians for an individual patient should be limited, as the number of prescribing physicians is an independent risk factor for ADEs [118]. Safe and effective hospital discharge principles are discussed separately. (See "Hospital discharge and readmission".)

A STEPWISE APPROACH TO PRESCRIBING — Presented below is one systematic approach to improving prescribing practices when managing older adults. Other systematic approaches have been described incorporating similar elements [119]. Regardless of the sequence of steps, what is essential in prescribing is to continually reappraise the patient’s medication regimen in light of his or her current clinical status, goals of care, and the potential risks/benefits of each medication.

A concept of “time to benefit” (TTB) in relation to drug prescribing for older patients with multiple morbidities can be applied to therapeutic decisions [120]. TTB, defined as the time to significant benefit observed in trials of people treated with a drug compared to controls, can be estimated from data from randomized controlled trials. Such information, not currently available, may in the future help guide decision making for specific drug prescribing in individual patients.

Review current drug therapy — Periodic evaluation of a patient's drug regimen is an essential component of medical care for an older person. Such a review may indicate the need for changes to prescribed drug therapy. These changes may include discontinuing a therapy prescribed for an indication that no longer exists, substituting a therapy with a potentially safer agent, changing drug dosage, or adding a new medication (table 8). A medication review should consider whether a change in patient status (eg renal or liver function) might necessitate dosing adjustment, the potential for drug-drug interaction, whether patient symptoms might reflect a drug side effect, or whether the regimen could be simplified [121]. Medication reviews are often not done in a systematic manner. A reasonable approach could be having a patient meet with a pharmacist within a few weeks of starting a new medication.

In a survey of Medicare beneficiaries, more than 30 percent of patients reported they had not talked with their doctor about their different medications in the previous 12 months [122]. Ideally, the clinician should ask the patient to bring to the visit all of the bottles of pills that they are using. Patients may not consider over-the-counter products, ointments, vitamins, ophthalmic preparations, or herbal medicines to be drug therapies and need to be specifically told to bring these to the visit.

Unintended medication discrepancies, particularly likely to occur at the time of hospital admissions, are a common source for medication errors. As an example, one study evaluated 151 patients (average age 77 years) admitted to general internal medicine clinical teaching units and found discrepancies in more than half between admission medication orders and the patient's usual drug therapies as identified by a medication history interview [123]. Most discrepancies involved unintentional omission of a maintenance medication and more than a third of these discrepancies had the potential to cause moderate harm.

Discontinue unnecessary therapy — Clinicians are often reluctant to stop medications, especially if they did not initiate the treatment and the patient seems to be tolerating the therapy. Sometimes, this exposes the patient to the risks for an adverse event with limited therapeutic benefit. A common example is the use of digoxin in older adults, often prescribed for indications that have not been well documented. Renal impairment or temporary dehydration may predispose older adults to digoxin toxicity [124]. Although digoxin therapy can be safely discontinued in selected nursing home residents, it is important to recognize that discontinuation in patients with impaired systolic function can have a detrimental effect [125]. (See "Overview of the therapy of heart failure due to systolic dysfunction".)

The decision to discontinue medication is determined in part by the goals of care for that patient and the risks of adverse effects for that patient. Targets for treatment, based on outcomes evidence from studies in younger patients, may not be appropriate for older adults [26]; thus clinical guidelines not targeted to older patients may foster overly-aggressive goals for management of hypertension or diabetes in the older adult population.

One approach to assessing whether a drug is truly necessary for a given patient is presented in an algorithm [126] (algorithm 1). In a feasibility study performed in a cohort of 70 community-dwelling patients seen for geriatric assessment, implementation of this algorithm led to recommendations to discontinue 58 percent of the medications they had been taking. Eighty-one percent of these medications were discontinued, 2 percent were restarted, and no significant adverse events were attributable to discontinuation over 13 month follow-up.

Some preventive and other therapies may no longer be beneficial to patients with short life expectancies [28]. The appropriateness of these therapies should be reconsidered when other medical conditions develop that impact a patient's long-term prognosis, unless the therapies are thought to increase comfort.

There are limited studies about how best to withdraw medications [27]. It is reasonable to gradually taper off most medications to minimize withdrawal reactions and to allow symptom monitoring, unless dangerous signs or symptoms indicate a need for abrupt medication withdrawal. Certain common drugs require tapering, including beta blockers, opioids, barbiturates, clonidine, gabapentin, and antidepressants.

Consider adverse drug events for any new symptom — Before adding a new therapy to the patient's drug regimen, clinicians should carefully consider whether the development of a new medical condition could be the presentation of an atypical adverse drug effect to an existing drug therapy. Many prescribing cascade scenarios have been identified (table 5). (See 'Prescribing cascades' above.) 

Consider nonpharmacologic approaches — Some conditions in older adults may be amenable to lifestyle modification in lieu of pharmacotherapy. The Trial of Nonpharmacologic Interventions in the Elderly (TONE) demonstrated that weight loss and reduced sodium intake could allow discontinuation of antihypertensive medication in about 40 percent of the intervention group [127,128]. (See "Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension", section on 'Lifestyle modifications'.)

Substitute with safer alternatives — When drug therapy is indicated for the older patient, it may be possible to substitute a safer alternative for the current regimen. As an example, in treatment of non-inflammatory arthritis, acetaminophen may provide adequate pain relief and be a safer alternative to NSAIDs [129]. (See "Initial pharmacologic therapy of osteoarthritis".) Numerous studies have documented adverse events associated with NSAID use in older persons, including gastrointestinal bleeds [130], renal impairment [131], and heart failure [132]. (See "Nonselective NSAIDs: Overview of adverse effects".)

Reduce the dose — Many adverse drug events are dose-related. When prescribing drug therapies it is important to use the minimal dose required to obtain clinical benefit. As an example, one study evaluated the relationship between prescribing of the newer atypical antipsychotic therapies (eg, olanzapine, risperidone, and quetiapine) and the development of parkinsonism in older adults [74]. Relative to those dispensed a low-dose, those dispensed a high-dose were more than twice as likely to develop parkinsonism (HR 2.07, 95% CI 1.42-3.02). As another example, one case-control study in patients over age 70 who received thyroid supplementation identified a correlation between risk of fracture and dose of levothyroxine, indicating the importance of testing for thyroid levels in this population and adjusting the dose accordingly [133].

Simplify the dosing schedule — When multiple medications are required, greater regimen complexity will increase the likelihood of poor compliance or confusion with dosing. Older adults, and particularly those with low health literacy, are not able to efficiently consolidate prescription regimens to optimize a dosing schedule [134]. The Institute of Medicine has proposed a standardized schedule for specifying medication dosing (morning, noon, evening, bedtime), recognizing that 90 percent of prescriptions are taken four or fewer times daily [135].

Simplifying the medication dosing schedule, when possible, is also important in the long-term care setting where nursing staff and time requirements for medication administration are substantial. A study illustrated that within a seven-hour shift, on a 20-bed unit, with two scheduled periods of medication administration, the process of administering medications to the residents accounted for a third of the nursing time [136]. This makes the nurse less available for other important patient care tasks.

Prescribe beneficial therapy — The fewer-the-better approach to drug therapy in older adults is often not the best response to optimizing drug regimens. Avoiding medications with known benefits to minimize the number of drugs prescribed is inappropriate. Patients must be informed about the reason to initiate a new medication, and what the expected benefits are.

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)

Basics topics (see "Patient information: Taking medicines when you're older (The Basics)" and "Patient information: Side effects from medicines (The Basics)")

SUMMARY AND RECOMMENDATIONS

The possibility of an adverse drug event (ADE) should always be borne in mind when evaluating an older adult; any new symptom should be considered drug-related until proven otherwise. Pharmacokinetic changes lead to increased plasma drug concentrations and pharmacodynamic changes lead to increased drug sensitivity in older adults. (See 'Introduction' above.)

Clinicians must be alert to the use of herbal and dietary supplements by older patients, who may not volunteer this information and are prone to drug-drug interactions related to these supplements. (See 'Herbal and dietary supplements' above.)

Various criteria sets exist identifying medications that should not be prescribed, or should be prescribed with caution, in older adults. Compliance with these lists of medications to be avoided is suboptimal. (See 'Inappropriate medications' above.)

Clinicians also underprescribe medications, such as statins, that could provide benefit for older adults. Clinicians may be better at avoiding overprescribing of inappropriate drug therapies than at prescribing indicated drug therapies. Patient financial constraints and unavailability of prescribed doses may contribute to medication underutilization. (See 'Underutilization of appropriate medication' above.)

Adverse drug events result in four times as many hospitalizations in older, compared with younger, adults. Prescribing cascades, drug-drug interactions, and inappropriate drug doses are causes of preventable ADEs. (See 'Adverse drug events (ADEs)' above.)

Adverse drug events are a particular problem for nursing home residents; atypical antipsychotic medications and warfarin are the most common drugs involved in ADEs in this population. (See 'Adverse drug events in long-term care setting' above.)

A step-wise approach to prescribing for older adults should include: periodic review of current drug therapy; discontinuing unnecessary medications; considering non-pharmacologic alternative strategies; considering safer alternative medications; using the lowest possible effective dose; including all necessary beneficial medications. (See 'A stepwise approach to prescribing' above.)

Use of UpToDate is subject to the Subscription and License Agreement.

REFERENCES

  1. Cho S, Lau SW, Tandon V, et al. Geriatric drug evaluation: where are we now and where should we be in the future? Arch Intern Med 2011; 171:937.
  2. Rowe JW, Andres R, Tobin JD, et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976; 31:155.
  3. Reidenberg MM, Levy M, Warner H, et al. Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clin Pharmacol Ther 1978; 23:371.
  4. Pomara N, Stanley B, Block R, et al. Adverse effects of single therapeutic doses of diazepam on performance in normal geriatric subjects: relationship to plasma concentrations. Psychopharmacology (Berl) 1984; 84:342.
  5. Pomara N, Stanley B, Block R, et al. Increased sensitivity of the elderly to the central depressant effects of diazepam. J Clin Psychiatry 1985; 46:185.
  6. Herings RM, Stricker BH, de Boer A, et al. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med 1995; 155:1801.
  7. Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther 1987; 240:159.
  8. Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008; 300:2867.
  9. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002; 287:337.
  10. Kelly JP, Kaufman DW, Kelley K, et al. Recent trends in use of herbal and other natural products. Arch Intern Med 2005; 165:281.
  11. Nahin RL, Fitzpatrick AL, Williamson JD, et al. Use of herbal medicine and other dietary supplements in community-dwelling older people: Baseline data from the ginkgo evaluation of memory study. J Am Geriatr Soc 2006; 54:1725.
  12. Nahin RL, Pecha M, Welmerink DB, et al. Concomitant use of prescription drugs and dietary supplements in ambulatory elderly people. J Am Geriatr Soc 2009; 57:1197.
  13. Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 1993; 328:246.
  14. Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355:134.
  15. Wold RS, Lopez ST, Yau CL, et al. Increasing trends in elderly persons' use of nonvitamin, nonmineral dietary supplements and concurrent use of medications. J Am Diet Assoc 2005; 105:54.
  16. Morris CA, Avorn J. Internet marketing of herbal products. JAMA 2003; 290:1505.
  17. Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 2007; 370:173.
  18. Alldred DP, Raynor DK, Hughes C, et al. Interventions to optimise prescribing for older people in care homes. Cochrane Database Syst Rev 2013; 2:CD009095.
  19. Wolfstadt JI, Gurwitz JH, Field TS, et al. The effect of computerized physician order entry with clinical decision support on the rates of adverse drug events: a systematic review. J Gen Intern Med 2008; 23:451.
  20. Ferner RE, Aronson JK. Communicating information about drug safety. BMJ 2006; 333:143.
  21. Tinetti ME, Bogardus ST Jr, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med 2004; 351:2870.
  22. Field TS, Gurwitz JH, Avorn J, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med 2001; 161:1629.
  23. Weng MC, Tsai CF, Sheu KL, et al. The impact of number of drugs prescribed on the risk of potentially inappropriate medication among outpatient older adults with chronic diseases. QJM 2013; 106:1009.
  24. Lai SW, Liao KF, Liao CC, et al. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. Medicine (Baltimore) 2010; 89:295.
  25. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ 1997; 315:1096.
  26. Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294:716.
  27. Steinman MA, Hanlon JT. Managing medications in clinically complex elders: "There's got to be a happy medium". JAMA 2010; 304:1592.
  28. Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006; 166:605.
  29. Mitchell SL, Teno JM, Kiely DK, et al. The clinical course of advanced dementia. N Engl J Med 2009; 361:1529.
  30. Givens JL, Jones RN, Shaffer ML, et al. Survival and comfort after treatment of pneumonia in advanced dementia. Arch Intern Med 2010; 170:1102.
  31. McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ 1997; 156:385.
  32. Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med 1991; 151:1825.
  33. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 1997; 157:1531.
  34. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163:2716.
  35. Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey. JAMA 2001; 286:2823.
  36. Hanlon JT, Schmader KE, Boult C, et al. Use of inappropriate prescription drugs by older people. J Am Geriatr Soc 2002; 50:26.
  37. Knight EL, Avorn J. Quality indicators for appropriate medication use in vulnerable elders. Ann Intern Med 2001; 135:703.
  38. Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med 2007; 167:781.
  39. Hilmer SN, Mager DE, Simonsick EM, et al. Drug burden index score and functional decline in older people. Am J Med 2009; 122:1142.
  40. Wilson NM, Hilmer SN, March LM, et al. Associations between drug burden index and falls in older people in residential aged care. J Am Geriatr Soc 2011; 59:875.
  41. Carrière I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med 2009; 169:1317.
  42. Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc 2011; 59:1477.
  43. Sura SD, Carnahan RM, Chen H, Aparasu RR. Prevalence and determinants of anticholinergic medication use in elderly dementia patients. Drugs Aging 2013; 30:837.
  44. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008; 168:508.
  45. Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008; 56:1333.
  46. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012; 60:616.
  47. Willcox SM, Himmelstein DU, Woolhandler S. Inappropriate drug prescribing for the community-dwelling elderly. JAMA 1994; 272:292.
  48. Lane CJ, Bronskill SE, Sykora K, et al. Potentially inappropriate prescribing in Ontario community-dwelling older adults and nursing home residents. J Am Geriatr Soc 2004; 52:861.
  49. Fialová D, Topinková E, Gambassi G, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA 2005; 293:1348.
  50. Rochon PA, Lane CJ, Bronskill SE, et al. Potentially inappropriate prescribing in Canada relative to the US. Drugs Aging 2004; 21:939.
  51. Lau DT, Kasper JD, Potter DE, et al. Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Arch Intern Med 2005; 165:68.
  52. Jano E, Aparasu RR. Healthcare outcomes associated with beers' criteria: a systematic review. Ann Pharmacother 2007; 41:438.
  53. Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007; 147:755.
  54. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365:2002.
  55. Gallagher P, O'Mahony D. STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteria. Age Ageing 2008; 37:673.
  56. Gallagher P, Ryan C, Byrne S, et al. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther 2008; 46:72.
  57. Hamilton H, Gallagher P, Ryan C, et al. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med 2011; 171:1013.
  58. Wehling M. Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged. J Am Geriatr Soc 2009; 57:560.
  59. Kuhn-Thiel AM, Weiß C, Wehling M, FORTA authors/expert panel members. Consensus validation of the FORTA (Fit fOR The Aged) List: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging 2014; 31:131.
  60. Shekelle PG, MacLean CH, Morton SC, Wenger NS. Acove quality indicators. Ann Intern Med 2001; 135:653.
  61. Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc 2007; 55 Suppl 2:S373.
  62. Higashi T, Shekelle PG, Solomon DH, et al. The quality of pharmacologic care for vulnerable older patients. Ann Intern Med 2004; 140:714.
  63. Steinman MA, Landefeld CS, Rosenthal GE, et al. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc 2006; 54:1516.
  64. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004; 291:1864.
  65. Federman AD, Adams AS, Ross-Degnan D, et al. Supplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart disease. JAMA 2001; 286:1732.
  66. Soumerai SB, Pierre-Jacques M, Zhang F, et al. Cost-related medication nonadherence among elderly and disabled medicare beneficiaries: a national survey 1 year before the medicare drug benefit. Arch Intern Med 2006; 166:1829.
  67. Rochon PA, Anderson GM, Tu JV, et al. Age- and gender-related use of low-dose drug therapy: the need to manufacture low-dose therapy and evaluate the minimum effective dose. J Am Geriatr Soc 1999; 47:954.
  68. Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 2007; 370:185.
  69. Onder G, Pedone C, Landi F, et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc 2002; 50:1962.
  70. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329:15.
  71. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279:1200.
  72. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002; 24:46.
  73. Avorn J, Bohn RL, Mogun H, et al. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. Am J Med 1995; 99:48.
  74. Rochon PA, Stukel TA, Sykora K, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med 2005; 165:1882.
  75. Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984; 2:1082.
  76. Avorn J, Gurwitz JH, Bohn RL, et al. Increased incidence of levodopa therapy following metoclopramide use. JAMA 1995; 274:1780.
  77. Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005; 165:808.
  78. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165:1095.
  79. Juurlink DN, Mamdani MM, Kopp A, et al. Drug-induced lithium toxicity in the elderly: a population-based study. J Am Geriatr Soc 2004; 52:794.
  80. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993; 153:1665.
  81. Battistella M, Mamdami MM, Juurlink DN, et al. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 2005; 165:189.
  82. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289:1652.
  83. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316:363.
  84. Tamblyn R, Abrahamowicz M, du Berger R, et al. A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc 2005; 53:233.
  85. Garg AX, Papaioannou A, Ferko N, et al. Estimating the prevalence of renal insufficiency in seniors requiring long-term care. Kidney Int 2004; 65:649.
  86. Breton G, Froissart M, Janus N, et al. Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function--the Three-City population-based study. Nephrol Dial Transplant 2011; 26:2852.
  87. Aronoff GR, Berns JS, Brier ME, et al.. Drug prescribing in renal failure: Dosing guidelines for adults, 4th ed, American College of Clinicians, Philadelphia 1999.
  88. Chertow GM, Lee J, Kuperman GJ, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA 2001; 286:2839.
  89. Gurwitz JH, Field TS, Judge J, et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med 2005; 118:251.
  90. Doshi JA, Shaffer T, Briesacher BA. National estimates of medication use in nursing homes: findings from the 1997 medicare current beneficiary survey and the 1996 medical expenditure survey. J Am Geriatr Soc 2005; 53:438.
  91. Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000; 109:87.
  92. Gurwitz JH, Field TS, Radford MJ, et al. The safety of warfarin therapy in the nursing home setting. Am J Med 2007; 120:539.
  93. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999; 47:30.
  94. Bronskill SE, Anderson GM, Sykora K, et al. Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact. J Am Geriatr Soc 2004; 52:749.
  95. Rochon PA, Stukel TA, Bronskill SE, et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med 2007; 167:676.
  96. US Food and Drug Administration. FDA MedWatch Safety Alert: RISPERDAL(risperidone), 2003. Available at: www.fda.gov/medwatch/SAFETY/2003/safety03.htm#risper (Accessed on February 09, 2006).
  97. www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm?show=27#6 (Accessed on February 09, 2006).
  98. Lenzer J. FDA warns about using antipsychotic drugs for dementia. BMJ 2005; 330:922.
  99. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:1934.
  100. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353:2335.
  101. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146:775.
  102. Onder G, Petrovic M, Tangiisuran B, et al. Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: the GerontoNet ADR risk score. Arch Intern Med 2010; 170:1142.
  103. Bates DW, Leape LL, Cullen DJ, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA 1998; 280:1311.
  104. Peterson JF, Kuperman GJ, Shek C, et al. Guided prescription of psychotropic medications for geriatric inpatients. Arch Intern Med 2005; 165:802.
  105. Gurwitz JH, Field TS, Rochon P, et al. Effect of computerized provider order entry with clinical decision support on adverse drug events in the long-term care setting. J Am Geriatr Soc 2008; 56:2225.
  106. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003; 289:1107.
  107. Field TS, Mazor KM, Briesacher B, et al. Adverse drug events resulting from patient errors in older adults. J Am Geriatr Soc 2007; 55:271.
  108. Forster AJ, Clark HD, Menard A, et al. Adverse events among medical patients after discharge from hospital. CMAJ 2004; 170:345.
  109. Cochrane RA, Mandal AR, Ledger-Scott M, Walker R. Changes in drug treatment after discharge from hospital in geriatric patients. BMJ 1992; 305:694.
  110. Gurwitz J. Case and commentary. Spotlight case. Double Trouble. Medicine, September 2005. Available at: www.webmm.ahrq.gov/case.aspx?caseID=104 (Accessed on March 27, 2006).
  111. The Institute for Safe Medication Practices. How to Take Your Medications Safely. Availabe at: http://www.ismp.org/Newsletters/consumer/alerts/Brochure.asp (Accessed on March 27, 2006).
  112. Cramer JA. Enhancing patient compliance in the elderly. Role of packaging aids and monitoring. Drugs Aging 1998; 12:7.
  113. Milton JC, Hill-Smith I, Jackson SH. Prescribing for older people. BMJ 2008; 336:606.
  114. Bell CM, Fischer HD, Gill SS, et al. Initiation of benzodiazepines in the elderly after hospitalization. J Gen Intern Med 2007; 22:1024.
  115. Calkins DR, Davis RB, Reiley P, et al. Patient-physician communication at hospital discharge and patients' understanding of the postdischarge treatment plan. Arch Intern Med 1997; 157:1026.
  116. Boockvar K, Fishman E, Kyriacou CK, et al. Adverse events due to discontinuations in drug use and dose changes in patients transferred between acute and long-term care facilities. Arch Intern Med 2004; 164:545.
  117. Hajjar ER, Hanlon JT, Sloane RJ, et al. Unnecessary drug use in frail older people at hospital discharge. J Am Geriatr Soc 2005; 53:1518.
  118. Green JL, Hawley JN, Rask KJ. Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population? Am J Geriatr Pharmacother 2007; 5:31.
  119. Scott IA, Gray LC, Martin JH, Mitchell CA. Minimizing inappropriate medications in older populations: a 10-step conceptual framework. Am J Med 2012; 125:529.
  120. Holmes HM, Min LC, Yee M, et al. Rationalizing prescribing for older patients with multimorbidity: considering time to benefit. Drugs Aging 2013; 30:655.
  121. George CJ, Jacobs LG. Geriatrics medication management rounds: a novel approach to teaching rational prescribing with the use of the medication screening questionnaire. J Am Geriatr Soc 2011; 59:138.
  122. Wilson IB, Schoen C, Neuman P, et al. Physician-patient communication about prescription medication nonadherence: a 50-state study of America's seniors. J Gen Intern Med 2007; 22:6.
  123. Cornish PL, Knowles SR, Marchesano R, et al. Unintended medication discrepancies at the time of hospital admission. Arch Intern Med 2005; 165:424.
  124. Forman DE, Coletta D, Kenny D, et al. Clinical issues related to discontinuing digoxin therapy in elderly nursing home patients. Arch Intern Med 1991; 151:2194.
  125. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993; 329:1.
  126. Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med 2010; 170:1648.
  127. Appel LJ, Espeland MA, Easter L, et al. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med 2001; 161:685.
  128. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998; 279:839.
  129. Bradley JD, Brandt KD, Katz BP, et al. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991; 325:87.
  130. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114:257.
  131. Gurwitz JH, Soumerai SB, Avorn J. Improving medication prescribing and utilization in the nursing home. J Am Geriatr Soc 1990; 38:542.
  132. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363:1751.
  133. Turner MR, Camacho X, Fischer HD, et al. Levothyroxine dose and risk of fractures in older adults: nested case-control study. BMJ 2011; 342:d2238.
  134. Wolf MS, Curtis LM, Waite K, et al. Helping patients simplify and safely use complex prescription regimens. Arch Intern Med 2011; 171:300.
  135. Wolf MS, Shekelle P, Choudhry NK, et al. Variability in pharmacy interpretations of physician prescriptions. Med Care 2009; 47:370.
  136. Thomson MS, Gruneir A, Lee M, et al. Nursing time devoted to medication administration in long-term care: clinical, safety, and resource implications. J Am Geriatr Soc 2009; 57:266.
Topic 3013 Version 33.0

Topic Outline

GRAPHICS

CALCULATORS

RELATED TOPICS

All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.